clinical-feasibility-assessor

Assess clinical and regulatory feasibility of Oral Mucositis drug candidates.

4|1|Updated Jan 8, 2024
One-click install
npx skills add https://github.com/OpenSourcePharmaFoundation/ospf-ayurveda-kg --skill clinical-feasibility-assessor
Or copy as Structured Prompt for Agent
Please help me install this Agent Skill.
Skill: clinical-feasibility-assessor
Source: https://github.com/OpenSourcePharmaFoundation/ospf-ayurveda-kg/tree/main/.claude/skills/clinical-feasibility-assessor
Command: npx skills add https://github.com/OpenSourcePharmaFoundation/ospf-ayurveda-kg --skill clinical-feasibility-assessor

SYSTEM DOCUMENTATION & REQUIREMENTS

What problem does it solve?

It helps you evaluate whether a drug candidate for Oral Mucositis (OM) can realistically progress from early development to actually reaching patients, considering regulation, timelines, costs, manufacturing, and real-world viability.

Core Features & Use Cases

  • Regulatory pathway selection: Matches likely FDA/EMA/AYUSH-type routes (e.g., NDA, 505(b)(2), DSHEA, device pathways) to the candidate’s nature (repurposed drug, natural extract, topical formulation).
  • Development cost and timeline estimating: Provides stage-based cost and duration ranges (preclinical through manufacturing/regulatory) and adjusts for OM-specific factors like topical vs systemic scope.
  • Feasibility checks across formulation, trials, commercial viability, and manufacturing: Flags common bottlenecks such as stability, GMP supply chain constraints, endpoint clarity, recruitment challenges, and IP risk.
  • Actionable decision output: Produces a structured assessment with go/no-go recommendation, top risks with mitigations, and a key de-risking next step.

Quick Start

Use the clinical-feasibility-assessor skill to generate an end-to-end feasibility report for the OM repurposing candidate you want to advance, including regulatory route, estimated timeline, cost range, trial design considerations, manufacturing risks, and a Go/No-Go recommendation.

Frequently Asked Questions about clinical-feasibility-assessor

High-intent search queries and answers about installing and using this skill.

FAQPage Schema
How do I assess the clinical feasibility of a drug repurposing candidate for Oral Mucositis?

To assess clinical feasibility for Oral Mucositis, evaluate the candidate against regulatory pathways, estimate development timelines and costs, and identify manufacturing or trial bottlenecks to generate a risk-ranked Go/No-Go decision.

What is the best regulatory pathway for a repurposed drug targeting Oral Mucositis?

The best regulatory pathway depends on the candidate's nature, matching repurposed drugs, natural extracts, or topical formulations to appropriate routes like NDA, 505(b)(2), DSHEA, or device pathways to optimize the approval strategy.

How do I estimate development costs and timelines for a topical Oral Mucositis treatment?

Estimate development costs and timelines by applying stage-based ranges from preclinical through manufacturing, adjusting for Oral Mucositis-specific factors like topical versus systemic scope and potential GMP supply chain constraints.

What manufacturing readiness bottlenecks affect clinical feasibility for Oral Mucositis candidates?

Manufacturing readiness bottlenecks affecting clinical feasibility include stability issues, GMP supply chain constraints, and formulation challenges that must be flagged during the assessment to ensure commercial viability.

When should I choose a 505(b)(2) regulatory route over DSHEA for an Oral Mucositis formulation?

Choose a 505(b)(2) route over DSHEA when the Oral Mucositis candidate relies on existing clinical data for therapeutic claims, whereas DSHEA applies to dietary supplements without disease-treatment claims.